5-Year Outcomes With Trametinib in BRAF V600 E/K–Mutant Melanoma
Posted: Thursday, February 14, 2019
According to a study published in the European Journal of Cancer by Caroline Robert, MD, PhD, of the Institut Gustave Roussy, Villejuif, France, and colleagues, the long-term use of trametinib is a viable option for patients with BRAF V600 E/K–mutant advanced or metastatic melanoma. In addition, based on the 5-year follow-up analysis of the phase III METRIC trial, some patients reaped a long-term survival benefit with the MEK inhibitor.
“The findings from this extended analysis of trametinib monotherapy may serve as the basis for future indirect comparisons against long-term findings from other ongoing trials of dabrafenib and trametinib combination therapy,” the investigators commented.
For this phase III study, the researchers randomly assigned 322 patients in a 2:1 ratio to receive trametinib (2 mg orally, once daily; n = 214) or chemotherapy (dacarbazine [1,000 mg/m2] or paclitaxel [175 mg/m2] intravenously, every 3 weeks; n = 108). They used 5-year outcomes to compare progression-free and overall survival data among the groups.
For the trametinib group, the median progression-free survival was 4.9 months, compared with 1.5 months for the chemotherapy group. “Landmark overall survival rates for trametinib versus chemotherapy arms at 1 year, 2 years, and 5 years were 60.9% versus 49.6%, 32.0% versus 29.4%, and 13.3% versus 17.0%, respectively,” they reported. Because of disease progression with chemotherapy, a total of patients 70 patients (65%) from the chemotherapy group crossed over to the trametinib group early in their treatment.
Disclosure: The study authors’ disclosure information may be found at ejcancer.com.